Therapeutic and safety considerations of nanoparticle-mediated drug delivery in pregnancy

Jeffrey Keelan, J.W. Leong, D. Ho, Killugudi Iyer

Research output: Contribution to journalArticlepeer-review

70 Citations (Scopus)


© 2015 Future Medicine Ltd. Advances in nanotechnology have resulted in the design of effective, safe and tissue-selective nanocarriers for delivering therapeutics to treat malignancies, infections and other diseases. In pregnancy, nanoparticle-based drug formulations could have the potential to selectively target either the placenta and/or fetus, enabling 'fetal-friendly' drugs to be administered in pregnancy with minimal risk of off-target effects. A considerable amount of research has been carried out on maternal-placental-fetal nanoparticle uptake, transfer and toxicity using rodent and ex vivo models. However, the development of placental targeting strategies and the therapeutic evaluation of nanoformulations in pregnancy remains in its infancy. While some promising avenues are currently under investigation, much work is needed to bring the advantages of nanoparticle-based drug therapy in pregnancy to clinical reality.
Original languageEnglish
Pages (from-to)2229-2247
Issue number14
Publication statusPublished - 2015


Dive into the research topics of 'Therapeutic and safety considerations of nanoparticle-mediated drug delivery in pregnancy'. Together they form a unique fingerprint.

Cite this